Back to News & Media

Press Releases

July 19, 2021

Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline

May 18, 2021

Frontier Medicines to Present at Two Upcoming Investor Conferences

March 31, 2021

Frontier Medicines Appoints Seasoned Executive Gregory Chow as Chief Financial Officer

March 30, 2021

Frontier Medicines Appoints Drug Development Expert David M. Goldstein, Ph.D., to its Board of Directors

January 8, 2021

Frontier Medicines to Present at the 39th Annual J.P. Morgan Healthcare Conference

December 2, 2020

Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets

November 11, 2019

Chemical & Engineering News Names Frontier Medicines One of Its 10 Chemistry Start-Ups to Watch

September 23, 2019

FierceBiotech Names Frontier Medicines One of Its “Fierce 15” Biotech Companies of 2019

July 31, 2019

Frontier Medicines Announces Three Executive Hires: Chief Scientific Officer, Chief Technology Officer & Head of Degrader Technologies

June 25, 2019

Frontier Medicines Launches with $67 Million to Develop Novel Medicines that Drug the “Undruggable” Targets Driving Human Disease